Phthalic acid esters, or phthalate esters, are generally well absorbed from the gastrointestinal tract following oral administration. Hydrolysis to the corresponding monoester metabolite, with release of an alcoholic substituent, largely occurs prior to intestinal absorption of the longer-chain alkyl derivatives such as di(2-ethylhexyl) phthalate (DEHP). Phthalate esters are widely distributed in the body, with the liver being the major, initial repository organ. Clearance from the body is rapid and there is only a slight cumulative potential. Short-chain dialkyl phthalates, such as dimethyl phthalate, can be excreted in an unchanged form or following complete hydrolysis to phthalic acid. Longer-chain compounds such as DEHP, however, are converted principally to polar derivatives of the monoesters by oxidative metabolism prior to excretion. A marked species difference in DEHP metabolism exists: primates (man, monkey, some rodent species) glucuronidate DEHP at the carboxylate moiety following hydrolysis of a single ester linkage, whereas rats appear to be unable to glucuronidate the monoester metabolite and oxidize the residual alkyl chain instead to various ketone and carboxylate derivatives. The major route of phthalate ester elimination from the body is urinary excretion. Certain phthalate esters are excreted in the bile but undergo enterohepatic circulation.
Introduction
It is the intent of this paper to furnish readers with a general background in phthalate ester pharmacokinetics, with emphasis on absorption, distribution, metabolism and excretion in several mammalian species. Subsequent papers in these proceedings address the absorption and metabolism of specific phthalates in more detail than is contained herein. The greatest amount of data, by far, has been collected on di(2-ethylhexyl) phthalate (DEHP), the most commonly used of the poly(vinyl chloride) (PVC) plasticizers. There seem to be sufficient similarities in some pharmacokinetic parameters of the compounds studied to date, however, to permit inferences to be drawn of the pharmacokinetics of dialkyl phthalate esters in general. Attempts to correlate similarities in pharnacokinetics to a generic pattern of toxicity for dialkyl phthalates await elucidation of probable mechanisms of toxic action. 
Chemical Structures and Properties
Structurally, phthalate esters consist of paired ester groups on a cyclohexatriene ring (benzenedicarboxylic acid) ( Table 1 ). The meta and para configurations are known as isophthalates and terephthalates, respectively. The ortho configuration, however, is implied in the generic use of the term, "phthalate esters." Phthalate esters are synthesized commercially by condensation of appropriate alcohols with phthalic anhydride as indicated in Table 1 Specific phthalate esters with short alkyl groups, such as dimethyl and di-n-butyl phthalates, are appreciably soluble (e.g., 0.5 g/100 ml) in water (1 (9) , including intestinal mucosal cells (10) . Extracellular enzymes present in the intestinal contents are also capable of hydrolyzing DEHP and other phthalate esters (10, 11). As shown in Table  3 , short-alkyl-chain congeners are more readily metabolized by intestinal contents than are longalkyl-chain congeners; the extent of completeness of the reaction is also inversely proportional to the concentrations of the diester compounds.
The hydrolytic activity of the intestinal contents dConcentration incorporated into feed.
eTime not reported. bDMP, dimethyl phthalate; DBP, di-n-butyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DOP, di-n-octyl phthalate.
'Percent metabolized in 16 hr. towards phthalate esters in vitro is heat (boiling) labile, but unaffected by either filtration of cellular material or by bacteriocidal sterilization of the gut (10, 11) . Hence, the hydrolytic activity appears to be enzymic in nature, though not of bacterial origin. Albro (13) . MEHP in blood, ostensibly a product of DEHP hydrolysis by blood esterases (14) , equilibrates between free and albumin-bound forms (13) .
Whether administered by oral or parenteral routes, DEHP and di-n-butyl phthalate (DBP), the two compounds studied most extensively, are rapidly cleared from the body (3) (4) (5) (6) 15 bTime between administration and examination. tion (e.g., urine, bile) and may, therefore, be inappropriately labeled as repositories. Daniel and Bratt (6) examined tissue accumulation of DEHP in rats by monitoring radioactivity in fat and liver after dietary exposure to 14C-DEHP.
A synopsis of their results is contained in Table 5 .
Steady-state concentrations in liver were achieved within a week of initiation of treatment, while that in fat required 2 weeks. The organ difference in time to achieve a steady-state level was mirrored by a difference in the rate of decline after removal of DEHP from the diet: radioactivity in the liver was reduced by 80% in 1 week, and was below detection limits within 3 weeks, while radioactivity in fat was reduced only to approximately one-third of the steady-state level within 3 weeks (Table 5 ). The steady-state tissue concentrations ofradioactivity were proportional to the concentration of DEHP in the diet, indicating that saturation of tissue accumulation had not occurred at up to 1000 ppm in the diet. In contrast to high-dose, oral studies in rats, significant fractions' of the cumulative dose of DEHP were reported to be retained for several months in the livers of rhesus monkeys infused (intravenously) repeatedly with very small amounts (cumulative doses of 21-69 mg/kg) of DEHP in blood (16) .
Surprisingly little is known of the abilities of phthalate esters to be transferred to offspring. Radioactivity was recovered from fetal tissues following treatment of the maternal animals with 14C-DEHP or 14C-diethyl phthalate (17 Dimethyl phthalate and, to a lesser extent, DBP can be excreted in urine as the parent, unchanged compounds or as their monoester metabolites (18) . Phthalate esters with longer chain lengths, however, such as DEHP, must undergo further modification after hydrolysis to the monoester to achieve sufficient polarity for renal excretion. The data in Table 6 indicate that several species of animals form glucuronide conjugates with the monoester metabolite of DBP at the free carboxylate group. The ferret, African Green monkey and man form glucuronide conjugates of MEHP, as well, but rats appear to be unable to do so (Table 6 ). Recent evidence indicates that hamsters, guinea pigs and mice also excrete glucuronide conjugates of MEHP (20) . The reason for the inability of rats to conjugate MEHP is unknown. In addition to glucuronidation, the residual alkyl chain is oxidized prior to urinary excretion of the metabolites (3, (21) (22) (23) (24) (25) (26) .
The inability of the rat to metabolize DEHP synthetically requires extensive oxidation of the remaining 2-ethylhexyl moiety to achieve water solubility. A schematic of the metabolism of DEHP in rats, as deduced by Albro et al. (19) , is shown in Eq. (2). The same general pathways have been documented for metabolism of the monoester derivatives of other dialkyl phthalate esters (2-7, 18). (18, 19) . Generally, the metabolism of phthalate esters is qualitatively unaffected by the route of administration (6, 7, 15, 18, 19) .
Excretion
The major route of phthalate ester elimination in both rodent and primate species, including man, is urinary excretion (Table 7) (23, 24) . Fecal elimination as a route of excretion has been evaluated for only a limited number of phthalate esters ( Table 7) . Elimination of di-n-butyl phthalate (DBP) in feces is nearly nil over a wide dose range. Appreciable percentages of DEHP appeared in feces when the compound was given by gavage, but whether the fecal material represented unabsorbed DEHP or biliary-exereted material was not ascertained (Table  7) . Similarly, only 4 and 9% of dietary DEHP at concentrations of 10 and 2000 ppm, respectively, were recovered from the feces of rats, but it is not known whether these materials were bile-excreted or unabsorbed chemical. (24) aNot reported. eliminated in the feces (88% in urine) of nonbile duct cannulated rats (Table 7) , indicating extensive enterohepatic cycling. As only 5% of a much larger dose of DBP, 500 mg/kg, was recovered from bile in 6 hr (Table 7) , hepato-biliary excretion of DBP metabolites would appear either to be saturated at high doses or to occur only after a specific period of time post absorption. The latter possibility, delayed biliary excretion, is suggested by the finding that only 10% of an intravenous dose of 50 mg/kg DBP was recovered in bile in 5 hr, in comparison to 44% of an oral dose of 60 mg/kg in 24 hr (Table 7) . Biliary metabolites of DBP include monobutyl phthalate, monobutyl phthalate glucuronide and oxidized derivatives of monobutyl phthalate glucuronide (3, 5, 21) .
DEHP can also undergo biliary excretion, as indicated by the report of Daniel and Bratt (6) that 14% of an oral dose of 2.6 mg/kg was recovered from bile. Extraction of 28% of an intravenous dose of 50 mg/kg DEHP from feces further indicates that biliary excretion can be a significant route of phthalate ester elimination ( Table 7) . The biliary metabolites of DEHP in rats were characterized as MEHP derivatives; none were glucuronide conjugates (6) . Although other studies did not specifically collect bile, an estimate of biliary excretion was obtained by separating fecally eliminated material into parent compound (presumably unabsorbed) and metabolites (presumably bile-excreted products). As only 8% of an oral gavage dose of 1.0 g/kg DEHP was isolated from feces as DEHP metabolites (Table 7) , either biliary excretion is not a major route of elimination in this dose range or, more likely, the biliary products are reabsorbed from the intestine and excreted in urine. Similar findings occurred in studies where DEHP was administered with food at concentrations of 10 or 2000 ppm (Table 7) . Hence, DEHP metabolites appear to be excreted in bile to an unknown extent, reabsorbed from the intestine, and ultimately eliminated in the urine.
Relationships of Phthalate Ester Pharmacokinetics to Toxic Effects
Speculation on possible relationships between comparative pharmacokinetics and toxicities are tenuous, at best, in the absence of well-defined mechanisms of action. The generally rapid clearance and low potential for tissue accumulation of the dialkyl phthalate esters, however, is at least consistent with, if not the cause of, their low toxic potencies in both acute and chronic studies (25) (26) (27) . The primate/rat difference in ability to form glucuronide conjugates of MEHP is suggestive of a major species difference in chemical metabolism.
Whether or not such a difference renders the rat an unsuitable model of human response to DEHP exposure awaits elucidation of the mechanisms of DEHP toxicity in rats. However, other species that differ from rats in their ability to glucuronidate MEHP (e.g., mice) respond with the same types of toxic injury as do rats (25) , indicating possible independence of chemical toxicity from the ability of the experimental subjects to form glucuronide metabolites. Yet to be determined are the precise mechanisms among several species of oxidation of the residual alkyl group and whether or not potential differences in the nature of the oxidation reaction (e.g., NADH-consuming or NADH-producing) could affect the toxic response. In light of the recent report that DEHP is a hepatocarcinogen in rats and mice (25) , these species differences or potential differences in DEHP metabolism provide a strong stimulus for studying the mechanisms of mammalian response to phthalate ester exposures.
